Role of Serial Plasma C.E.A. Assays in Detection of Recurrent and Metastatic Colorectal Carcinomas

Mackay, Alan; Patel, Shashikant; Carter, S.; Stevens, U.; Laurence, D. J. R.; Cooper, Edward H.; Neville, A. Munro

doi:10.1136/bmj.4.5941.382

Cited by 103 publications

(22 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CT (Hansen et al, 1974) and these non-specific factors may be the cause of the elevation in some cases of bronchial carcinoma. The non-specific causes are, however, unlikely to be the cause of a level in excess of 40 ,ug/l and this level should therefore be regarded as definite evidence of a CEA-producing tumour (Mackay et al, 1974).…”

mentioning

confidence: 99%

Biochemical markers in bronchial carcinoma

McKenzie¹,

Evans²,

Hillyard³

et al. 1977

Br J Cancer

View full text Add to dashboard Cite

mentioning

confidence: 99%

Biochemical markers in bronchial carcinoma

McKenzie¹,

Evans²,

Hillyard³

et al. 1977

Br J Cancer

View full text Add to dashboard Cite

“…Most studies to date have concentrated on colorectal carcinomas (Booth et al, 1974b;Mach et ai., 1974;Mackay et al, 1974;Sorokin et al, 1974;Turner, 1975). We have been carrying out a combined study of a large number of patients in Leeds and the South-west Thames Region after clinicalIy curative surgery.…”

mentioning

confidence: 99%

“…• ·Series A, Mackay et al, (1974); Series B, Mach et al, (1974); Series C, Booth et al, (1974). ···No evidence of recurrence.…”

mentioning

confidence: 99%

“…Selection of suitable patients would be facilitated in disease where rises in a tumour index substance Mackay et al (1974) and LoGerfo and Herter (1975 The lXI-globulin, AFP, is a product of the fetal liver, gastrointestinal tract, and yolk sac which appears in the fetal circulation (Gitlin, 1971). Its principal present clinical use is in obstetrics, where high concentrations are present in the amniotic fluid in association with fetuses having neural tube defects, certain forms of nephrosis, or a 45/XO chromosomal constitution (Allan et al, 1973;Brock et al, 1973;Leek et al, 1973;Seller et al, 1973;Seller et al, 1974).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Biochemical Monitoring of Cancer: A Review

1976

Self Cite

View full text Add to dashboard Cite

“…In the management of breast cancer patients a tumour marker of unique clinical value has not yet been established. Carcinoembryonic antigen (CEA) (1), an important parameter for disease progression as well as for the early detection of disease recurrence in gastrointestinal cancer (2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13), is of less clinical significance in breast cancer, since pathologically elevated serum levels of CEA were recorded in only about 50% of cases (14,15). Therefore, the development of further diagnostic parameters is of urgent necessity in order to establish methods for a direct surveillance of tumour growth and control of the efficacy of therapeutic efforts.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Serum β2-Microglobulin and Carcinoembryonic Antigen (CEA) in the Follow-Up of Breast Cancer Patients

Staab¹,

Ahlemann²,

Anderer³

et al. 1981

CCLM

View full text Add to dashboard Cite

Staab, Ahlemann, Anderer, Hiesche and Rodatz: Serum 02-microglobulin and carcinoembryonic antigen in breast cancer pat icnts 339 J. Clin. Chem. Clin. Biochem. Vol. 19, 1981, pp. 339-345 Summary: Using commercially available radioimmune test kits, serial determinations of serum j32-microglobulin and CEA were performed in 337 patients, who had been treated for breast cancer by modified radical mastectomy and radiotherapy. The pre-therapeutic data indicated a higher incidence of pathological j32-microglobulin and CEA levels in patients with distant metastases than in patients with localized disease. However, this finding did not allow the conclusion of a direct complementarity of j32-microglobulin and CEA as tumour markers, since the group of patients with distant metastasis contained a high percentage of elderly patients who generally can be expected to have elevated 02-microglobulin serum concentrations. Therefore, the correlation of the clinical course of malignant disease and the incidence of relapses with the changes of serum |32-microglobulin and CEA concentrations was examined during the posMreatment surveillance: 7/9 cases (78%) with local recurrence and 46/73 cases (63%) with distant spread of disease were not indicated in the |32-microglobulin follow-up by pathologic serum concentrations, whereas in the CEA follow-up only 1/9 and 2/73 false negative indications were registered. The poor correlation suggests that serum 02-microglobulin is not directly tumour associated in breast cancer and does not fulfill the criteria of a tumour marker. Comparison of Serum ß2-Microglobulin and Carcinoembryonic Antigen (CEA) in the Follow-Up of Breast Cancer Patients Vergleich von Serum ß2?Mikroglobulin und CEA in der klinischen Überwachung von Patienten mit Brustkrebs

show abstract

Role of Serial Plasma C.E.A. Assays in Detection of Recurrent and Metastatic Colorectal Carcinomas

Cited by 103 publications

References 8 publications

Biochemical markers in bronchial carcinoma

Biochemical markers in bronchial carcinoma

Biochemical Monitoring of Cancer: A Review

Comparison of Serum β2-Microglobulin and Carcinoembryonic Antigen (CEA) in the Follow-Up of Breast Cancer Patients

Contact Info

Product

Resources

About